Edwards Lifesciences Corp
Edwards Lifesciences Corp/ US28176E1082 /
EW
|
30.05.2024 19:32:33
|
Zm.
+1,39
|
Wolumen |
Bid19:32:40 |
Ask19:32:40 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
88,42USD
|
+1,60%
|
1,04 mln
Obrót: 70,12 mln |
88,41Wolumen Bid: 200 |
88,46Wolumen Ask: 100 |
53,17 mldUSD |
- |
38,20 |
Opis działalności
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.
Zarząd & Rada nadzorcza
| CEO |
| Bernard J. Zovighian |
| Zarząd |
| Scott B. Ullem, Donald E. Bobo Jr., Todd J. Brinton, Daveen Chopra, Dirksen J. Lehman, Jean-Luc Lemercier, Wayne Markowitz, Christine Z. McCauley, Joseph Nuzzolese |
| Rada nadzorcza |
| Michael A. Mussallem, Kieran T. Gallahue, Leslie S. Heisz, Martha H. Marsh, Nicholas J. Valeriani, Paul A. LaViolette, Ramona Sequeira, Steven R. Loranger, Bernard J. Zovighan |
Dane firmy
| Nazwa: |
Edwards Lifesciences Corp. |
| Adres: |
One Edwards Way,Irvine, California 92614, USA |
| Telefon: |
+1-949-250-2500 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.edwards.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
83,04% |
| Data IPO: |
03.04.2000 |
Główni akcjonariusze
| Inne |
|
59,45% |
| Vanguard Group, Inc. (The) |
|
8,54% |
| Blackrock Inc. |
|
8,54% |
| State Street Corporation |
|
4,44% |
| Capital International Investors |
|
4,25% |
| Alliancebernstein L.p. |
|
3,37% |
| Bank Of New York Mellon Corporation |
|
3,01% |
| Wellington Management Group, LLP |
|
2,61% |
| Brown Advisory Inc. |
|
2,32% |
| Inne |
|
3,47% |
